Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 646 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Stereotactic Radiosurgery Clear all
Recruiting Phase 2 Interventional

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

NCT05554302
View directory record Official record
Conditions
Brain Metastases, Brain Cancer
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)

NCT05178472
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Spine
Interventions
Immunotherapy, Stereotactic Radiosurgery, Vertebroplasty
Other · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

NCT01146054
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG)
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Early Phase 1 Interventional

MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer

NCT02683200
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
Interventions
Image-Guided Adaptive Radiation Therapy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT05915442
View directory record Official record
Conditions
Oligometastatic Prostate Cancer
Interventions
Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Catherine Spina
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT07393867
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer

NCT01162200
View directory record Official record
Conditions
Early Stage Breast Cancer
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 22, 2026, 5:03 PM EDT
Active, not recruiting Not applicable Interventional

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881
View directory record Official record
Conditions
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
Interventions
Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT), Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

NCT07578116
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
59
States / cities
Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

NCT03399552
View directory record Official record
Conditions
Malignant Mesothelioma (MPM)
Interventions
Avelumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neurocognitive Decline in Patients With Brain Metastases

NCT03508752
View directory record Official record
Conditions
Brain Metastases
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

NCT04923776
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

NCT04990921
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palliative Radiation and Pembrolizumab
Combination Product
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

NCT02052648
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
Interventions
Indoximod, Temozolomide, Bevacizumab, Stereotactic Radiation
Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Castro Valley, California • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

NCT01511081
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy)
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors

NCT00632281
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

NCT01730937
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
Sorafenib, stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
41
States / cities
Berkeley, California • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

NCT03889119
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.
Radiation
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

NCT02830165
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

NCT01896271
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
IL-2, Stereotactic Ablative Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Early Phase 1 Interventional

5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme

NCT03291990
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 22, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

NCT01721603
View directory record Official record
Conditions
BRAFV600E Melanoma Patients
Interventions
Dabrafenib, Gamma Knife Radiosurgery, Trametinib
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 5:03 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

NCT03991962
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
341
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 5:03 PM EDT